Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28039223 | 0.91 | MAPT (0.68) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL20157601 | 0.86 | MAPT (0.64) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL20157900 | 0.85 | MAPT (0.58) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL23457081 | 0.84 | RAB9A (0.58) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL31682610 | 0.84 | RAB9A (0.58) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL7251926 | 0.83 | POLB (0.73) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL21362614 | 0.82 | TP53 (0.52) | MAPTRAB9AKMT2AMEN1MAPK1 | |
| SCHEMBL1820102 | 0.82 | POLB (0.71) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL4842294 | 0.82 | POLB (0.71) | POLBHPGDMAPTRAB9ANPSR1 | |
| SCHEMBL3809736 | 0.81 | MAPT (0.82) | POLBHPGDMAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319326-B2 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer | JUBILANT BIOSYS LIMITED (IN) | 2022-05-03 | — | — | US | disclosed |
| US-20200331926-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | JUBILANT BIOSYS LIMITED (IN) | 2020-10-22 | — | — | US | disclosed |
| US-10689390-B2 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer | JUBILANT BIOSYS LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180282345-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | JUBILANT BIOSYS LIMITED (IN) | 2018-10-04 | — | — | US | disclosed |
| EP-3277683-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | Jubilant Biosys Ltd. (IN) | 2018-02-07 | — | — | EP | disclosed |
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| WO-2016157221-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | JUBILANT BIOSYS LIMITED (IN) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016157221-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | JUBILANT BIOSYS LIMITED (IN) | 2016-10-06 | — | — | WO | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140005169-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2646446-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012075456-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075456-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075383-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075383-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | POLB 588/4885HPGD 978/4885MAPT 356/4885 |
| US-11319326-B2 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer | BRD3, BRD4, BRD2 | POLB 169/4885HPGD 1689/4885MAPT 309/4885 |
| US-20180282345-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | BRD4, BET1, BRD3 | POLB 92/4885HPGD 1423/4885MAPT 563/4885 |
| US-20140005169-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | POLB 588/4885HPGD 978/4885MAPT 356/4885 |
| US-10689390-B2 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer | BRD4, BET1, BRD3 | POLB 92/4885HPGD 1423/4885MAPT 563/4885 |
| US-20200331926-A1 | TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER | BRD4, BET1, BRD3 | POLB 92/4885HPGD 1423/4885MAPT 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.